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Abstract
Background: Around 47–74% of patients with hereditary hemorrhagic telangiectasia (HHT) have hepatic vascular
malformations (HVMs); magnetic resonance images (MRI) of the central nervous system (CNS) might show in T1
sequences a hyper-intensity signal in different areas, mainly in the basal ganglia (BG) as consequence of manganese
(Mn) deposits as observed in cirrhotic patients. These patients might suffer from different neuropsychiatric disorders
(hepatic encephalopathy). In HHT patients, even in the presence of hepatic shunts, hepatocellular function is usually
preserved. Additionally, Mn shares iron absorption mechanisms, transferrin and CNS transferrin receptors. In iron
deficiency conditions, the Mn may harbor transferrin and access BG. The objectives were to describe frequency of
BG Mn deposit-induced lesions (BGMnIL) in HHT patients, its relationship with iron deficiency anemia (IDA) and
HVMs. Finally, explore the association between neuropsychological and motor consequences. We performed a
cross-sectional study. We determined HHT patients with or without BG-MnIL by the MRI screening of the CNS. We
included all patients with lesions and a random sample of those without lesions. All patients underwent standardized
and validated neuropsychological assessment to evaluate BG actions. Results were analyzed with multiple logistic
regression, adjusting for potential confounders.
Results: Among 307 participants from a cohort included in the Institutional HHT Registry, 179 patients had MRI
performed and Curaçao Criteria ≥3. The prevalence of BG-MnIL was 34.6% (95%CI 27.69-42.09). While neuropsychological
symptoms were present in all patients, BG-MnIL patients performed poorly in three of the neuropsychological
tests (serial dotting, line tracing time, number connection test A). HVMs frequency in BG-MnIL was 95.1%, versus
71.4% in those without lesions (p < 0.001). IDA frequency was 90.3% versus 54% (p < 0.001). When IDA is present,
estimated risk for BG-MnIL is remarkably high (OR 7.73, 95%CI 2.23–26.73). After adjustment for possible confounders
(gender, age, presence of HVMs), IDA was still associated with increased risk of BG-MnIL (adjusted OR 6.32, 95% CI 2.32–
17.20; p < 0.001).
Conclusions: Physicians should assess BG-MnIL in HHT patients in CNS-MRI. IDA and HVMs present increased risk of
lesions. Patients with BG-MnIL have neuropsychological impairment, and they might benefit from sparing IDA, or
undergoing future therapeutic options.
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Background
The hereditary hemorrhagic telangiectasia (HHT) or
Rendu Osler-Weber syndrome is an autosomal domin-
ant inherited disorder characterized by an abnormal de-
velopment and remodeling of the blood vessels. It
affects around 1-5000/8000 individuals worldwide [1–
6]. Clinical diagnosis of HHT is based on Curaçao cri-
teria (spontaneous recurrent epistaxis, telangiectases in
typical locations, visceral arterio-venous malformations
-lung, liver, brain, and central nervous system- and
first-degree family member with HHT) and/or genetic
testing [3, 7].
Hepatic vascular malformations (HVMs) may be
present in 41–74% of cases according to the screening
method used and genotype [8]. The HVMs are more fre-
quently found in patients with HHT2 [8–10]. Only 8%
of patients have symptoms related to HVMs such as
high output cardiac failure with secondary pulmonary
hypertension, portosystemic encephalopathy, portal
hypertension syndrome, steal syndrome or ischemic ne-
crosis in the biliary tree. Symptoms related to HVMs are
rare in patients before 50 years old [11]. In HHT pa-
tients, like cirrhotic patients and porto-systemic shunts,
the central nervous system magnetic resonance images
(MRI) in T1 sequences might show a hyper-intensity sig-
nal in different areas, mainly in the basal ganglia (BG)
[12]. The patients with advanced hepatic disease who
present Mn in their BG might suffer from different
neuropsychiatric disorders known as hepatic encephal-
opathy or minimal hepatic encephalopathy [13, 14].
Studies in animals and humans have demonstrated
that the T1 signal hyper-intensity found in different
brain structures in patients suffering from liver diseases
corresponds to manganese (Mn) deposits which are fa-
cilitated by hyper-ammonemia and/or hypermanganese-
mia [15]. On the other hand, the Mn uses the same
absorption (Divalent Metal Transporter 1-DMT1), trans-
port and deposition mechanisms as iron. In turn, iron
deficiency might lead to the increase of manganese ab-
sorption which is harbored by the transferrin. High
levels of transferrin receptors may be found in many
CNS areas, predominantly in BG [13, 15–17]. Even in
the absence of hepatic disease, iron deficiency collabo-
rates with the increase of Mn absorption and deposition
in the BG leading to a toxic effect [13]. The frequent
iron deficiency anemia due to nose and gastrointestinal
bleeding in HHT patients plus the presence of HVMs
may result in a proper scenario to facilitate the deposit
of manganese in the CNS.
Nowadays, in HHT patients, the prevalence of deposits
of Mn in the BG, their pathophysiologic mechanisms
and clinical implications are not well established [18,
19]. The purpose of this study is to determine the preva-
lence of BG-MnIL and their risk factors in HHT popula-
tion and to evaluate possible neuropsychological and
motor consequences.
Methods
We conducted a cross sectional study in a multidiscip-
linary HHT care unit located at the “Hospital Italiano de
Buenos Aires”, a University hospital. The HHT Unit
consists of different specialists majored on HHT who as-
sist HHT patients from different countries of our region
from the moment of diagnosis. There is no severity or
manifestation-type referral bias, the patients are referred
for clinical evaluation and treatment. All patients under-
went standardized screening assessment recommended
for HHT patients [3].
Study population was made up of adult patients with
confirmed HHT (3 or more Curaçao clinical criteria
and/or genetic test) who were included in our Institu-
tional Registry of HHT -clinicaltrials.gov NCT01761981-
and had a brain MRI screening performed. We excluded
those who refused to the informed consent. Other exclu-
sion criteria were neurologic or psychiatric diseases, psy-
chiatric treatment, alcoholism, hepatic diseases different
from HHT HVMs and portal hypertension. The protocol
was approved by our Institutional Review Board. The
study was performed from June 2012 to December 2014.
Study procedures
The patients included in the Institutional registry of
HHT who met the inclusion criteria for this study, were
contacted by phone and/or e-mail for an interview with
the principal investigator inviting them to participate in
the study. In the interview, study purpose and proce-
dures were explained in detail, and patients were re-
quested for the informed consent. Patients were
included prospectively. Once included, MRI images were
send to a neuro-radiologist, laboratories and hepatic
studies were registered and a random sample of those
presenting BG-MnIL and those without BG-MnIL were
derived for neuropsychological evaluation.
Serra et al. Orphanet Journal of Rare Diseases  (2017) 12:92 Page 2 of 10
All screening MRI of the CNS from patients included
in this study underwent exhaustive revision of their im-
ages focusing on BG and other locations with hyper-
intensity images consistent with Mn deposits and vascu-
lar malformations. Prevalent cases were defined in those
patients in which BG-MnIL were detected in the screen-
ing MRI. The MRIs were performed with RM equipment
1.5 T with and without gadolinium sequences. Axial and
sagittal images in T1 and T2 diffusion sequences were
performed as standard. Data processing was blind to pa-
tient clinical information in a Siemens commercial work
station (Syngo). The MRI images were analyzed by two
independent high trained neurorradiologyst through vis-
ual inspection in all cases. They define BG-MnIL with
hyperintensity images in T1 in the BG area.
A randomized sample of patients -simple random
sampling method- with BG-MnIL and without BGMnIL
underwent a detailed neurological examination by neu-
rologists specialized in movement disorders to detect
extrapyramidal signs and symptoms. All patients were
assessed with a comprehensive neuropsychological bat-
tery conducted by neuropsychologists with experience in
brain disease. The neuropsychological assessment proto-
col included the “Psychometric Hepatic Encephalopathy
Score” (PHES), Fig. 6, see Additional file 1.
The PHES has been standardized in several countries,
such as Germany, Italy, Spain, India, Korea and Mexico.
The quantitative measurement of performance in each sub-
test of PHES and the tests, was judged as deficient, when
the value was 1 SD or more below means score in stan-
dardized scale [20, 21]. As the Argentinian standardization
of this battery is not finished, the results of the NCT-A,
NCT-B, and SDT were measured in seconds, including the
time needed to correct any errors, and the result of DST
was measured in points. The results of the LTT were mea-
sured as both the time needed to complete the test (LTTt,
seconds) and as the number of errors (LTTe) [20, 22, 23].
Poor outcomes are represented by prolonged times and
greater number of errors.
To screen the global cognitive performance of patients
we used the known Mini-Mental State Examination
(MMSE) [24]. The MMSE or Folstein test is a 30-point
questionnaire that is used extensively in clinical and re-
search settings to measure cognitive impairment [25].
Hepatocellular function was assessed as standard in
HHT patients’ medical care, with liver function test, pro-
thrombin time or factor V dosage. The hepatic vascular
malformations were identified by standardized Doppler
ultrasound and/or enhanced triphasic multislice com-
puted tomography (MSCT) and classified by physicians
with high training in HHT images [3, 26, 27]. We in-
cluded in this study the worst values a patient could
have regarding hepatic compromise in 1 year time from
MRI assessment.
Anemia and iron deficiency state was evaluated, as usual
blood tests are included in our HHT screening protocol:
Hematocrit, hemoglobin, ferritin, iron serum levels and
transferrin saturation. We define anemia with hemoglobin
below 12,5 g/dl or 11,5 g/dl in males and females respect-
ively. We considered iron deficiency anemia (IDA) when
ferritin was below 20 ng/ml, when inflammatory condi-
tions was ruled out, or when transferrin saturation was
below 16% [28, 29]. We included in this study the worst
values a patient could have in 1 year time from MRI
assessment.
Statistical analysis
Patients included in this study were considered the de-
nominator for the BG-MnIL prevalence estimation. We
reported prevalence with 95% confidence interval.
Comparisons between groups with BG-MnIL and
without BG-MnIL were tested with chi square test and
Man Whitney.
We estimated risk of presenting BG-MnIL in patients
with IDA and reported Odds Ratios with 95% confidence
intervals. Multivariate logistic regression analysis was
performed to adjust for confounding variables (age, gen-
der and HVMs).
To stablish BG-MnIL impact on neuropsychological
symptoms we performed a linear regression model for
each test and adjust for confounders (IDA and HVMs).
We evaluated if the interaction between IDA and HVMs
could affect neuropsychological symptoms when pre-
senting BG-MnIL. We considered statistical significance
p values <0.05. All analysis was performed with STATA
software vs 14.
Sample size
Manganese deposits prevalence was estimate in the total
HHT cohort. For the objective of comparing the pres-
ence of neurological affectation in BG-MnIL patients,
we calculated a sample size considering an estimated dif-
ference of 35% (40% of patients with BG-MnIL would
have psychological symptoms and only 5% of those with-
out lesions), power on 80% and alpha 0.05, we estimated
20 patients with BG-MnIL and 20 without it.
Results
From a cohort of 307 patients included in the Institu-
tional HHT registry, we included 179 patients who had
MRI performed and Curaçao Criteria > = 3. See patient
flow chart (Fig. 1).
The estimated BG-MnIL prevalence was 34.6% (95%CI
27.6%- 42% -62/179 patients) in HHT cohort.
We found a high prevalence in patients of female gen-
der (69.3%) and young patients (median age 46 years,
interquartile range 25). IDA and HVMs were more
prevalent in HHT patients with BG-MnIL (Table 1).
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The most frequent CNS structure affected was the glo-
bus pallidus (40 patients), other sites were hypophysis
(11), midbrain (10) and others: putamen and caudate (1),
periaqueductal grey matter (1), protuberance (1). Char-
acteristic lesions are seen in brain MRI as shown in
Figs. 2, 3 and 4.
All kind of HVMs were more frequent in the BG-
MnIL group. The most frequent were the telangectases,
even more so, in many patients the telangectases were
the only kind of HVM detected (isolated telangectases in
7/62 patients with BG-MnIL and in 33/117 patients
without them) (Fig. 5).
Basal Ganglia Manganese Induced Lesions Risk
The risk of having BG-MnIL in IDA patients was esti-
mated with a crude OR 7.95 (CI 95% 3.13–20.13) p <
0.001. The association between BG-MnIL and IDA ad-
justed by gender, age, presence of hepatic vascular mal-
formations was OR 6.32 (CI 95% 2.32–17.20, p < 0.001).
The risk of having BG-MnIL in patients with HVM was
estimated with a crude OR 7.73 (CI 95% 2.23–26.73) p <
0.001. The association between BG-MnIL and hepatic vas-
cular malformations adjusted by IDA was OR 6.49 (CI95%
1.75–24.02) p 0.005, and adjusted by IDA, age and gender
was OR 5.31 (CI95% 1.39–20.32) p 0.014.
Fig. 1 Flow chat of participants. There are two groups, 62 patients presented BG-MnIL and 117 patients without BG-MnIL. The figure shows
patients who presented neuropsychological evaluation in each group
Table 1 Basal characteristics
Characteristics HHT patients (179) BG-MnIL patients (62) Patients without BG-MnIL (117) P values
Female gendera 69.3% (124) 75.8% (47) 65.8% (77) 0.16
Age in yearsb 46 (25) 55.5 (20) 41 (25) 0.058
Iron Deficiency Anemiaa 58.1% (104) 87.1% (54) 42.7% (50) <0.001
Hepatic Vascular Malformationsa 80% (128/159) 95.1% (58) 71.4% (70) <0.001
Ferritin ng/mlb 14 (30.7) 14.1 (9.75) 22 (24.7) 0.004
Hemoglobin g/dlb 11.8 (3.8) 10 (7.7) 12.2 (3.1) 0.004
Hematocrit %b 36 (10) 30.9 (14) 37 (9.35) 0.004
TF Saturation %b 15% (17.6) 9.5 (12) 19 (15) 0.003
a% (absolute frequency), b medians (interquartile range). Reference values: Hematocrit: 37% in men and 36% in women, Hemoglobin 12.5 g/dl in men and 11.5 g/dl
in women, Ferritin: 20 ng/ml, Transferrin Saturation (TF) >16%
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Neuromotor assessment and Neuropsychological assessment
results
Twenty-four patients with BG-MnIL and 15 patients
without BG-MnIL underwent neurological motor assess-
ment focused on abnormal movements. Eleven patients
with BG-MnIL (47%) were affected in a neuromotor
level. Patients without BG-MnIL did not present any
motor neurological affection. The different clinical find-
ings were tremors 7 (28%), rigidity/Parkinsonism 2
(16.5%), myoclonus 1 (4.7%), restless legs syndrome 1
(4.7%).
The same patients with BG-MnIL and without BG-
MnIL underwent the neuropsychological assessment
protocol. We found neuropsychological failures in both
groups in tests that assessed speed and finely-tuned
motor control when comparing to original standards.
Nevertheless, the failures have been significantly greater
in the group with BG-MnIL when considering times and
numbers of errors. We also found failures in tests that
assessed focus and concentration, in both groups. We
have not found relevant failure in executive functions.
We could not find cognitive features within patients
who shared the Mn location. The only patient that
passed all the tests had Mn only in adenohypophysis.
Neither the age nor the education showed impact on the
performance. In Table 2 we presented comparison of ab-
solute values of time in seconds for Serial Dotting Test,
Line Tracing Test-time, Number Connection Test A and
B, number of errors in Line Tracing Test-errors and
points in Digit Symbol Test. Worse time or numbers of
errors are interpreted as poorer neuropsychological
performance.
Given that all patients presented at least one neuro-
psychological symptom was present in all patients, BG-
MnIL, both with and without BG-MnIL, we estimated
the BG-MnIL effect in a lineal regression for each
neuropsychological test and estimated coefficients. We
found statistical significance in Line Tracing Test -er-
rors, Serial Dotting Test and Number Connection Test
A. We performed an adjusted model by gender, age, IDA
and HVMs and an interaction term between IDA and
HVMs. After adjusting, the impact of having BG-MnIL
is still significant for Number Connection Test A and
Line Tracing Test- errors (Table 3).
Discussion
This study presented basal ganglia manganese-induced
lesions prevalence in HHT, their risk factors and neuro-
logical impact. We found BG-MnIL in one third (34.6%)
of patients with HHT mainly in the globus pallidus. IDA
was identified as an independent risk factor for BG-
MnIL. IDA is a frequent event in HHT being the main
Fig. 2 Psychometric Hepatic Encephalopathy Score. The figure
shows a schematic representation of test included in PHES battery
Fig. 3 BG-MnIL MRI image. T1 sequence Brain MRI showing
hyperintensity signal in the basal ganglia as consequence of
manganese deposition
Fig. 4 Manganese deposits in CNS structures. Coronal MRI T1 image
showing hyperintensity signal in the midbrain as consequence of
manganese deposition
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modifiable risk factor for manganese deposits. Thusly,
the present study highlights a non-well known clinical
feature secondary to IDA in HHT patients [1].
We also found that BG-MnIL might be responsible for
neuropsychological and motor impairment that remains
unnoticed for majority of patients in their daily activities.
This scenario could suggest a greater risk of lifelong
damage exposure. On the contrary, this would probably
require prompt diagnostic and therapeutic actions.
Although there are few reports of small case series
which describe hyperintense basal ganglia lesions in HHT
population, none of them evaluated their neurological
impact. Moreover, they only postulated HVM as their
main risk factor leaving aside ferropenic states [12].
Ihara K et al. reported two non-HHT patients in whom
portosystemic shunts were associated to BG-MnIL in
the presence of Mn in workplace exposure [15]. K
Yoshikawa et al. reported the first case suggesting IDA
as a potential risk factor in a young woman with HHT,
who presented parkinsonism, portosystemic shunts and
elevated Mn blood levels who present BG-MnIL [14].
In this report they postulated physiopathology mecha-
nisms for IDA involvement but the neuropsychological
description is limited.
Fig. 5 Manganese deposits in CNS structures. Sagittal MRI T1 image showing hyperintensity signal in the adenohypophysis as consequence of
manganese deposition
Fig. 6 Hepatic vascular malformations in HHT patients. This figure shows the distribution of the different kind of hepatic vascular malformations
in patients with BG-MnIL and without BG-MnIL
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There are other studies that explained the relation be-
tween iron deficiency and BG-MnIL but in a non-HHT
population Also manganese related encephalopathy is well
descripted in cirrhotic patients, welders and patients re-
ceiving parental nutrition. Normally, the liver carries out
the manganese clearance through the biliary excretion. In
the case of hepatic disease as cirrhosis or portosystemic
shunts, the manganese clearance may be decreased lead-
ing to high serum levels of this cation. The increase of am-
monia in those patients may lead to an increase of
glutamine and decrease of glutamate, myoinositol and
choline in astroglia. In turn, these changes lead to an in-
crease of vascular permeability facilitating the access and
deposits of manganese in the CNS [30, 31]. Manganese
produces a neuronal toxic effect leading to reversible or ir-
reversible neuronal injury, depending on the duration of
the manganese exposition [13]. It has also been associated
to parkinsonism and psychometrics test deficit caused by
dopaminergic neurotransmission impairment in basal
ganglia [32]. According to Weissenborn there was no rela-
tion between MRI hyperintensity density and neuromotor
or neuropsychological state in cirrhotic patients, though
neurologic symptoms were present according to hepatic
lesion severity [33].
Although in the present study we did not performed
MRI measurements of BG-MnIL hyperintensity to estab-
lish association between neurological symptoms and in-
tensity gradient, we found different neuropsychological
impairment in those without lesion, supporting our hy-
pothesis. Despite our population suffering from HHT,
this study collaborates with the comprehension on the
basal ganglia diseases and their clinical consequences,
perhaps commonly with subclinical presentation.
We have also noticed that other CNS structures were
harbouring Mn, and that the adenohypophysis seemed
affected in many cases. However, further studies are
needed to evaluate the association between adenohy-
pophysis lesions and endocrine symptoms. Neuro-
psychological and motor failures shown in BG-MnIL
patients correlate with motor and neuropsychological
failures related with speed task execution, concentration,
focus, finely-tuned motor control and extrapyramidal
symptoms, in concordance to the globus pallidus affection,
the most frequent location of Mn in the CNS in this study.
While PHES is validated in many countries there is no
Argentinian validation. There are available validations and
standard scores for Italian, Spanish and Mexican popula-
tion. As the Argentinian population might have similar
educational level to those countries, we believe it might be
an evaluation battery that could be comprehensive and
properly used in our population. Still, as we lack of Argen-
tinian validation and standard scores for our population,
we compare unprocessed time values and number of er-
rors. Worse results represent that the task slows down.
HHT hepatic disease is assessed through hemodynamic
consequences like high output cardiac arrest, secondary
pulmonary hypertension, and portal hypertension syn-
drome with or without encephalopathy or ischemic dam-
age of the biliary tree due to different kinds of vascular
malformations [3]. It has been reported that only around
8% of patients with HVMs have shown the symptoms
mentioned above in which the neurological consequences
are caused only by portosystemic shunts. Contrary to the
general knowledge that hepatic telangectases do not rep-
resent a relevant clinical problem, we have found that only
the presence of hepatic telangectases might be sufficient,
Table 3 BG-MnIL impact on neurological symptoms. Lineal Regression for each test (crude and adjusted)
Neuropsychological test Crude Coefficient (95%CI) P Adjusted Coefficient* (95%CI) p
Serial Dotting Test 21.1 (2.3–40) 0.02 17.0 (−4.6–38.7) 0.12
Line Tracing Test (time) 31.4 (−4.7–67) 0.08 25.5 (−16.8–67.8) 0.22
Line Tracing Test (errors) 6.5 (0.1–13) 0.04 7.6 (0.1–15.1) 0.04
Number Connection T A 15.0 (2.7–27) 0.01 14.7 (0.3–29.1) 0.04
Number Connection T B 19.9 (−3.3–43) 0.09 20.5 (−7.0–48.0) 0.13
Digit Symbol (points) −3.6 (−10–3) 0.28 −2.3 (−10.3–4.8) 0.47
Adjusted by gender age, IDA, HVMs and interaction IDA*HVMs
Table 2 Neuropsychological test values by group
Neuropsychological test Patients with
BG-MnIL (n 24)
Patients without
BG-MnIL (n 15)
p
Serial Dotting Test -in
seconds-
68 (57–85) 59 (54–62) 0.01
Line Tracing Test (time) -
in seconds-
117 (86–147) 93 (80–121) 0.09
Line Tracing Test (errors) -
number of errors-
9 (2.5–17.5) 6 (1–8) 0.08
Number Connection T A -
in seconds-
40 (28–55) 33 (24–38) 0.03
Number Connection T B -
in seconds-
82 (60–106) 69 (57–86) 0.11
Digit Symbol (points) -
number of points-
43 (36–49) 47 (40–52) 0.37
MMSE -score number- 30 (29–30) 30 (29–30) 0.39
Numbers as median (25–75 percentiles)
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in certain cases, to ease the manganese deposition in the
CNS in presence of IDA. It becomes significantly import-
ant since IDA and hepatic telangectases are very frequent
among HHT patients.
On the other hand, not all HHT patients with HVMs
showed manganese in the BG, making this a necessary
risk factor might not be a sufficient explanation. There-
fore, we studied another mechanism to understand this
phenomenon. As we mentioned, we found that the iron
deficiency anemia is the main factor to ease the manga-
nese deposits in the basal ganglia. In iron deficiency
states, manganese harbours the DMT-1, transferrin and
its receptors, which are mainly present with high density
in the BG area, especially in the globus pallidus [14]. We
have noticed that the IDA increases 6-fold the risk of
Mn deposition in HHT patients regardless of the pres-
ence of HVMs, gender and age, being the most import-
ant risk factor we found in our research. Therefore,
minimizing the IDA in the affected patients might re-
duce the magnitude of Mn deposits in the CNS improv-
ing the neuropsychological and neuromotor failures.
Hence, iron deficiency and IDA might explain per se
some psychomotor impairments, since the normal iron
map distribution in the brain is the same as dopamine
[34]. Moreover, the iron is a co-factor of catecholamine
synthesis pathway. Is clear that iron deficiency and IDA
cause cognitive, learning and behavioral impairments in
children and perhaps in adults [35]. Some authors have
found that iron supplementation in adults with IDA cor-
related with a better mental and speed task performance
[36]. Nevertheless, in our study BG-MnIL is associated
to neuropsychological symptoms independently from
IDA and HVMs. Thus, further studies must face if these
findings have some impact in everyday life of HHT pa-
tients because in our population none of our patient self-
reported complaints. We could not assess time extent of
iron deficiency anemia so we cannot demonstrate that be-
ing depleted of iron chronically could worsen manganese
deposits or their neuropsychological impairment. We be-
lieve that the question that follow these results, first, is
whether BG-MnIL is reversible, as happens in cirrhotic
patients after liver transplantation and if their impact in
neuropsychological tests will improve after IDA treatment.
Limitations.
The study design could not allow us to establish caus-
ality, nevertheless we highlight BG-MnIL and the associ-
ation with iron deficiency anaemia should be consider in
the HHT population.
There might be an overlap between minimal hepatic
encephalopathy and symptoms associated with basal
ganglia dysfunctions especially in patients with high por-
tosystemic shunt. Nevertheless, in our study, only one
patient presented evidence of hemodynamic comprom-
ise by portal hypertension.
The number of neuropsychological evaluations might
be insufficient, all the same, we found some differences
in this random selection of patients.
When we considered PHES standardized scores from
other countries validations, all patients have at least one
abnormal test in comparison to other standards. It
would be necessary to validate neuropsychological tests
in Argentinean population and contrasts our findings.
Nevertheless, we believe that there have been no bias in
the evaluation itself (specialized and standardized evalu-
ation) or in population bias (random sample of cases
and controls).
We decided to report test values demonstrating differ-
ences between groups. Although this is not the standard
procedure, in some tests, values are sufficiently different
in both groups, suggesting poorer outcomes in BG-
MnIL. Prolonged execution times and number of errors
might demonstrate enough neuropsychological lesion
impact. Further studies will be required to determine
long term impact of BG-MnIL.
We are concerned about the external validity of our
findings, however, patients in this study are heteroge-
neous regarding their disease features, age, gender and
socio-cultural or educational level, increasing the
generalization of the results.
Conclusion
We consider that patients with HHT should be assessed
for BG-MnIL in their screening MRI, especially in those
with HVMs and iron deficiency anemia. Probably it
would be also useful to make a neuropsychological
evaluation in those who presents lesions. There is still
need to elucidate whether these lesions are reversible
and if iron deficiency anemia treatment could contribute
to ameliorate Manganese deposits.
Additional file
Additional file 1: The Psychometric Hepatic Encephalopathy Score
(PHES) is a “paper and pencil” screening test battery, designed for the
diagnosis of minimal hepatic encephalopathy [20, 37]. This validated tool
includes the following five tests: the line tracing test (LTT) with two
scores for the same test: time and numbers of errors -motor speed and
accuracy-, the serial dotting test (SDT) -motor speed-, the digit symbol
test (DST) -associative learning; graphomotor speed, cognitive processing
speed, visual perception, working memory-, the number connection test
A (NCT-A) -psychomotor speed; visual scanning efficiency, sequencing,
attention, concentration- and the number connection test B (NCT-B)
-attention set shifting ability, psychomotor speed, visual scanning
efficiency, sequencing, attention, concentration- all test are represented
in Fig. 6 [38]. These tests examine motor speed and accuracy, visual
perception, visuospatial orientation, visual construction, concentration,
attention and to a lesser extent memory [22]. (DOCX 15 kb).
Abbreviations
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